LungLife AI, Inc.
(the "Company" or
"LungLife")
Data Supporting LungLB to be
Presented at the Association for Molecular
Pathology
LungLife AI (AIM: LLAI), a developer of
clinical diagnostic solutions for lung cancer, is pleased to
announce that our two abstract submissions to the Association for
Molecular Pathology1 (AMP)
have been accepted for both presentation at their flagship 2024
Annual Meeting & Expo in Vancouver, BC,
Canada from November 19-23rd, and also for
publication in the November 2024 issue of The Journal of Molecular
Diagnostics.
The acceptance of our abstracts for
both presentation and publication is a recognition of the interest
in, and significant potential of, our LungLB® test. They provide us
with an exciting opportunity to further raise market awareness and
understanding of the LungLB® test as we highlight the results of
two important LungLB® studies demonstrating the analytic and
clinical validity of the test to a broad range of clinical
laboratories, healthcare providers, and industry
representatives.
In addition, the data presented
serve to expand the clinical evidence for the LungLB® test which is
important to encourage and support adoption of the test by
centres.
Commenting on
the acceptance, Paul Pagano, Chief Executive Officer of LungLife,
said:
"We are excited to have these two abstracts
accepted for both presentation and publication by the AMP and
believe this marks another important step in the pathway to
commercialisation.
AMP brings together a diverse community of
physicians, scientists, and laboratory professionals from academic
and community medical centres, government, and industry. We are
looking forward to furthering discussions that allow us to
demonstrate our commitment to advancing early detection of lung
cancer and making a significant impact in this critical area of
healthcare."
Full details of the abstracts are as
follows:
Abstract Title:
Analytical Validation of
the LungLB test: a blood-based 4-color FISH assay for the
evaluation of indeterminate pulmonary nodules
Presenter: Eric Vail, MD,
Cedars-Sinai Medical Center
Abstract # 1874291
Abstract Title:
Clinical Validation of
LungLB: a Circulating Genetically Abnormal Cell-based Classifier
for Indeterminate Lung Nodule Evaluation
Presenter: Paul Pagano,
PhD
Abstract # 1874647
For further
information please contact:
|
LungLife AI,
Inc.
|
www.lunglifeai.com
|
|
Paul Pagano, CEO
|
via
investors@lunglifeai.com
|
|
David Anderson, CFO
|
|
|
|
|
|
Investec Bank plc (Nominated Adviser &
Broker)
|
Tel: +44 (0)20 7597
5970
|
|
Virginia Bull / Lydia Zychowska/
Sara Wallace
|
|
|
|
|
|
Goodbody
(Joint Broker)
|
Tel: +44 (0) 20 3841
6202
|
|
Tom Nicholson / Cameron Duncan
|
|
|
|
|
Notes
1. Originally
founded in 1995, AMP advances the clinical practice, science, and
excellence of molecular and genomic laboratory medicine through
education, innovation, and advocacy to enable highest quality
health care, and is the primary resource for expertise, education,
and collaboration in one of the fastest growing fields in
healthcare. AMP members influence policy and regulation, and
develop practice guidelines on the national and international
levels, ultimately serving to advance innovation in the field and
protect patient access to high quality, appropriate
testing.
About LungLife
LungLife AI is a developer of
clinical diagnostic solutions designed to make a significant impact
in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the
Company's LungLB® test is designed to deliver additional
information to clinicians who are evaluating indeterminate lung
nodules. For more information visit
www.lunglifeai.com
Our Purpose is to be a driving force in the
early detection to lung cancer. And our Vision is to invert
the 20:80 ratio such that in years to come at least 80% of lung
cancer is detected early.
